The nine-price HPV vaccine since May 1, 2018 signed a supplementary agreement, has been awarded in 5 provincial units, the above products bidding, promotion, sales work as planned to actively promote.

Medical Network August 15 August 13 night, the Intelligent Flying Biology released 2018.5 Annual report, the company's first half to achieve operating income of 2.072 billion yuan, compared with the same period last year 365.42%; The net profit attributable to the owner of the parent company was 683 million yuan, which grew by 297.22% over the same period last year;

The net profit, which is attributable to the owner of the parent company deduction of Non-recurrent gains, is 685 million yuan, up 306.92% from the same period last year. At present, there are 5 kinds of autonomous products in the sale, including Ac-hib vaccine, ACYW135 meningitis polysaccharide vaccine, Hib vaccine, AC meningitis polysaccharide combined vaccine, micro-card;

5 kinds of agents or agreements to promote the sale of products, respectively, Zhejiang Pu Kang's Hepatitis A live attenuated vaccine and Merck 23-valent pneumonia, inactivated hepatitis A vaccine, bivalent HPV vaccine and nine-price HPV vaccine. For the intelligent flying creature, this year, the focus of the outside world, is the company's sales agent HPV vaccine sales in the domestic market. Data show that in November 2017, the company agent of the Mershadons price of HPV received a grant issued; May 2018, the company also received the national Drug

The nine-price HPV vaccine issued by the supervisory Authority, "Certificate of the issue of biologics". During the reporting period, the intelligent flying creature vigorously launched the four-price HPV vaccine as the representative of the import Agent Product sales.

Up to now, the four-price HPV has been in the country 29 provincial units won the bid, promotion, sales work is also in progress. In addition, the five-valent rotavirus vaccine has been imported since April 19, 2018 Drug registration Since the certificate, has been in 2 provincial units won the bid;

The nine-price HPV vaccine has been awarded to 5 provincial units since the signing of the supplemental Agreement on May 1, 2018. Semi-annual reports show that in the first half of 2018, Intelligent FEI Biological agent of four-price HPV batch issued 2.6248 million, nine-price HPV batch issued 6022.

and public information shows, Intelligence Fei Biological agent of the four-price HPV vaccine, in 27 provinces (municipalities) priced 798 yuan/branch, nine-price HPV vaccine price 1298 yuan/branch. In the first quarter of this year, the top ten circulating shareholders of intelligent flying organisms, a number of institutions appeared to reduce.

Half-yearly report shows that the top ten circulating shareholders of intelligent flying is not a significant change in positions.

In addition, the Chi Fei in the semi-annual report, the company 2018 1~ September's main business income, net profit and other important financial indicators than the same period a year ago will have a larger increase. The reasons for the growth of performance include: The company Ac-hib vaccine sales maintained a good growth trend; Agent products Four-price HPV vaccine in mainland China 29 provincial units won the bid, sales continued to increase steadily; The five-valent rotavirus vaccine has been awarded to 2 provincial units since it was issued with the registration certificate of imported Drugs April 19, 2018;